Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity*

POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN

1977 • 1,196 citations

Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.

1989 • 643 citations

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1980 • 544 citations

The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

1992 • 456 citations

Geographical/Interracial Differences in Polymorphic Drug Oxidation

1995 • 431 citations

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1992 • 406 citations

MEDICAL NEMESIS

1974 • 377 citations

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1993 • 370 citations

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

1994 • 301 citations

Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors

1993 • 300 citations

The use of caffeine for enzyme assays: A critical appraisal

1993 • 282 citations

Inhibition by fluoxetine of cytochrome P450 2D6 activity

1993 • 259 citations

Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities

1991 • 258 citations

Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

1993 • 214 citations

Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking

1991 • 214 citations

The relationship between paroxetine and the sparteine oxidation polymorphism

1992 • 204 citations

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

1993 • 189 citations

Inhibition of Alprazolam and Desipramine Hydroxylation In Vitro by Paroxetine and Fluvoxamine

1995 • 174 citations

Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection

1977 • 155 citations

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.

1995 • 151 citations

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

1992 • 150 citations

Influence of patient-related variables on clozapine plasma levels

1990 • 141 citations

Genetically variable metabolism of antidepressants and neuroleptic drugs in man

1993 • 136 citations

The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.

1992 • 130 citations

CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine

1996 • 108 citations

Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans

1995 • 92 citations

The pharmacogenetics of the selective serotonin reuptake inhibitors

1993 • 90 citations

Clinical Pharmacokinetics of Fluvoxamine

1994 • 85 citations

Caffeine metabolism in a healthy Spanish population: N-Acetylator phenotype and oxidation pathways

1994 • 74 citations

Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects

1992 • 64 citations

New Psychotherapeutic Drugs

1994 • 21 citations